Stephen Turner - Protea Biosciences Chairman, CEO and Pres
Chairman
Mr. Stephen C. Turner is Chairman of the Board, Chief Executive Officer of the Company. positions he has held since founding the Company in July, 2001. From 1999 to 2001 he served as President and CEO of Quorum Sciences, Inc. From 1984 to 1997 he was President and CEO of Oncor, Inc. He founded Bethesda Research Laboratories, Inc. in 1975 and served as its Chairman and CEO from 1975 to 1983, at which time BRL became the molecular biology division of Life Technologies, Inc. Prior to commencing his career in biotechnology, Mr. Turner held the position of Director of Marketing for the Clinical Microbiology Division of Becton, Dickinson Co. He received his B.A. from Stanford University in 1967. In 1994 he received the Ernst Young Entrepreneur of the Year Award in Life Sciences for the Washington D.C. Region. Mr. Turner was appointed to serve as a director of the Company because he is the founder of Protea and his deep knowledge of our products and market opportunity led the board to determine that he should serve as a director. since 2001.
| Age | 69 |
| Tenure | 23 years |
| Phone | 304-292-2226 |
| Web | http://www.proteabio.com |
Protea Biosciences Management Efficiency
The company has return on total asset (ROA) of (104.33) % which means that it has lost $104.33 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.9) %, meaning that it created substantial loss on money invested by shareholders. Protea Biosciences' management efficiency ratios could be used to measure how well Protea Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10.93 M in liabilities. Protea Biosciences has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Protea Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Protea Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Protea Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Protea to invest in growth at high rates of return. When we think about Protea Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Anthony Hsieh | Loandepot | 59 | |
| Gary Bagley | HE Equipment Services | 71 | |
| Gerard Holthaus | Willscot Mobile Mini | 68 | |
| Christopher Lynch | Federal Home Loan | 59 | |
| Michael Angelini | The Hanover Insurance | 73 | |
| Cynthia Egan | The Hanover Insurance | 66 | |
Management Performance
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 |
Protea Biosciences Leadership Team
Elected by the shareholders, the Protea Biosciences' board of directors comprises two types of representatives: Protea Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protea. The board's role is to monitor Protea Biosciences' management team and ensure that shareholders' interests are well served. Protea Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protea Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonard Harris, Independent Director | ||
| Stephen Turner, Chairman, CEO and Pres | ||
| Gregory Kilby, COO and VP of Operations | ||
| Edwin Roberson, Independent Director | ||
| Stanley Hostler, VP, Secretary, Director and Member of Audit Committee | ||
| Steven Antoline, Independent Director | ||
| Edward Hughes, CFO | ||
| Scott Segal, Independent Director | ||
| Ed Roberson, Independent Director | ||
| Patrick Gallagher, Director | ||
| Andrew Zulauf, Independent Director | ||
| Josiah Austin, Independent Director | ||
| Matthew Powell, Chief Science Officer and VP of RandD | ||
| David Halverson, Vice President Chief Business Officer | ||
| Maged Shenouda, Director |
Protea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc bb equity is not an easy task. Is Protea Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 | |||
| Operating Margin | (261.55) % | |||
| Current Valuation | 11.29 M | |||
| Shares Outstanding | 8.03 M | |||
| Shares Owned By Insiders | 49.85 % | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | (0.23) X | |||
| Price To Sales | 0.14 X | |||
| Revenue | 2.07 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protea Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protea Biosciences' short interest history, or implied volatility extrapolated from Protea Biosciences options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protea Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Protea Biosciences information on this page should be used as a complementary analysis to other Protea Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Protea OTC BB Equity
If you are still planning to invest in Protea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Protea Biosciences' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |